The annual Controlling Cancer Summit is an international academic event with plenty of opportunity for networking and debate. In an informal setting, this meeting will bring you up to date with current research and thinking regarding screening, prevention and treatment in this ever-growing field. Presenting at this event, we will have a variety of clinicians, academics and members of the pharmaceutical industry; we encourage presentations from the wide spectrum of cancer research, development and healthcare professionals.

This event has CPD accreditation

www.lifescienceevents.com/Cancer2016

#Cancer2016
Contents

AGENDA ..................................................................................................................... 6

Day 1: Therapeutic Intervention .................................................................................. 6

  Introduction by the Chair ......................................................................................... 6
  New therapeutic approaches and repurposed drugs for targeting of glioma stem cells and treatment of glioblastoma ................................................................. 6
  Non-Natural Nucleosides as Therapeutic Agents Against Glioblastoma ............ 6
  ONCASTATIC EFFECTS OF MELATONIN: ROLE OF MITOCHONDRIAL FUNCTION ................................................................. 6
  HIGH CONCENTRATION OF MELATONIN POTENTIATES THE TOXICITY OF RADIO- AND CHEMOTHERAPY IN HEAD AND NECK CANCER CELLS IN CULTURE AND IN VIVO ........................................................................ 6
  MACROPHAGE-BASED TECHNOLOGY FOR CANCER TREATMENT: M3 SWITCH PHENOTYPE EFFECTIVELY RESTRICTS TUMOR GROWTH IN VITRO AND IN VIVO ................................................................. 6
  Adoptive T cell Therapy for Cancer ........................................................................ 6
  Stem Cell based Therapies for Cancer: Mechanism and Translation into Clinics .... 6
  Dendritic cell derived exosomes for cancer therapy ............................................... 6
  Precious metals for cancer treatment - a novel approach ....................................... 6
  Oral Presentations ................................................................................................... 6
  EFFICACY OF A NEW PHARMACEUTICAL FORMULATION OF MELATONIN IN PREVENTING RADIOTHERAPY-INDUCED MUCOSITIS ................................................................. 6
  TARGETING CANCER CELL PROTEIN SYNTHESIS WITH BETA-CARBOLINE DERIVATIVES TO COMBAT BRAIN CANCERS ........................................................................................................... 6
  Immunotherapy for cancer dormancy .................................................................... 6
  Targeted nanomedicines in cancer therapy .............................................................. 6
  Question Time ......................................................................................................... 6

AGENDA ..................................................................................................................... 7

Day 2: Genetic Factors and Influences ....................................................................... 7

  Introduction by the Chair ......................................................................................... 7
  DNA damage repair and p53 gene in platinum-drug resistance ................................... 7
  Crosstalk between cell death modalities as anticancer target .................................. 7
  DNA repair gene polymorphisms as risk factors and chemotherapy response predictors for lung adenocarcinoma in Serbia ........................................................................ 7
  DNA methylation in epithelial-to-mesenchymal transition ...................................... 7
  Oral Presentation ................................................................................................... 7
  WNT SIGNALLING PATHWAY IS TARGETED IN MENINGIOMA ......................... 7
  Recognition of LINE-1 derived DNA by the cGAS-STING pathway leads to inflammation in Fanconi Anemia ................................................................................ 7
  NQO1, GSTM1, and GSTT1 genetic polymorphisms and the risk of developing cancer among Filipinos ................................................................. 7
  The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis ................................................................. 7
AGENDA .............................................................................................................................. 8

Day 3: Biomarkers and Diagnostics .................................................................................. 8

Introduction by the Chair ................................................................................................. 8

Using chemical and biological data for targeted compound selection and biomarker discovery in cancer and beyond .................................................................................................................. 8

DNA methylation in early detection and risk prediction of women specific cancers .......... 8

CYP3A variation, hormone levels, breast cancer risk and prognosis ................................. 8

Cognitive impairment in patients with glioblastoma: single institution experience ............. 8

OMICS biomarkers and their implication in cancer control ................................................ 8

Oral Presentation .................................................................................................................. 8

POOR KNOWLEDGE OF CERVICAL CANCER AND CERVICAL DYSPLASIA AMONG WOMEN IN ABAKALIKI, NIGERIA: THE NEED FOR HEALTH EDUCATION FOR CANCER PREVENTION. ...................................................... 8

Responsive lanthanide complexes for imaging of key cell cycle regulators and inhibition of tumor cells ........................................................................................................................................... 8

Oral Presentations .................................................................................................................. 8

MOLECULAR DETERMINANTS OF SENSITIVITY AND RESISTANCE TO FGFR TARGETED THERAPY IN FGFR2-AMPLIFIED GASTRIC CANCERS .................................................................................. 8

INNOVATIVE APPROACHES IN METABOLOMICS FOR UNDERSTANDING DRUG RESISTANCE IN BREAST CANCER ......................................................................................................... 8

Question Time: ......................................................................................................................... 8

Nucleosomics® - Revolutionising Cancer Diagnostics .......................................................... 8

Signalling therapy for cancer: from target proteins to target signalling networks ............... 8

ABOUT THE SPEAKERS ......................................................................................................... 9

Anthony J. Berdis .................................................................................................................... 9

Andreas Bender .................................................................................................................... 9

Irina Babina, ........................................................................................................................... 9

Ivana Boljevic, ....................................................................................................................... 9

Suzanne Egyházi Brage, ........................................................................................................ 9

Annelise Carvalho, ................................................................................................................ 9

Isolda Romero-Canelón, ....................................................................................................... 10

Alice Carrier, ........................................................................................................................ 10

Leandro Castellano, .............................................................................................................. 10

Christine Dufes, ...................................................................................................................... 10

Marc Diederich, ..................................................................................................................... 10

Germaine Escames, .............................................................................................................. 10
FREQUENTLY ASKED QUESTIONS ABOUT OUR EVENTS

ABOUT THIS EVENT

Jing Jie Yu,
Martin Widschwendter,
Gary Ka
Mukesh Verma,
Umber Saeed,
Khalid Shah,
Bozena Smolkova,
Nives Pećina
Gloria Ogechukwu NGWU,
Bethr
David Meiri
Masoud H. Manjili,
Igor Malyshev,
Chame
Ana Misir Krpan,
David Henry,
Ana Guerra-Libredo,
Gray Kueberuwa,
Hala Gali-Muhtasib,
Susanne Gabrielsson,
Nikolaos Georgopoulos,
Jessica Guerra,

Office:
47 High Street, Barnet, Herts, EN5 5UW, UK

Registered number:
Trading Address:
Euroscicon Ltd,
Highstone House, 165 High Street, Barnet, Herts.
10
11
11
11
11
11
11
11
12
12
12
12
12
13
13
13
14
14
14
14
14
14
14
14
14
15
15
16
17
**AGENDA**

PLEASE NOTE: DUE TO SECURITY CONTROLS, THERE IS NO ACCESS TO THE VENUE BEFORE 9AM

(Invited Talk times include 5 – 10 minutes for question; Oral presentations include 2-3 minutes for questions)

**Day 1: Therapeutic Intervention**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Organizer/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:45</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>09:45 – 10:25</td>
<td>Introduction by the Chair</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeting non death domain-containing TNFR family members for cancer therapy: direct, carcinoma cell-specific death by CD40 signalling</td>
<td><strong>Dr Nikolaos Georgopoulos</strong>, Department of Biological Sciences, School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom</td>
</tr>
<tr>
<td>10:25 – 10:50</td>
<td>New therapeutic approaches and repurposed drugs for targeting of glioma stem cells and treatment of glioblastoma</td>
<td><strong>Professor Chaya Brodie</strong>, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, United States</td>
</tr>
<tr>
<td>10:50 – 11:15</td>
<td>Non-Natural Nucleosides as Therapeutic Agents Against Glioblastoma</td>
<td><strong>Dr Anthony J. Berdis</strong>, Ph.D., Chair, IACUC Committee, Associate Professor of Chemistry and Biology, Cleveland State University, Cleveland, OH, USA</td>
</tr>
<tr>
<td>11:15 – 11:45</td>
<td>Poster Review and Exhibitions</td>
<td>Refreshments provided</td>
</tr>
<tr>
<td>11:45 – 12:15</td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td>11:45 – 11:55</td>
<td>ONCASTIC EFFECTS OF MELATONIN: ROLE OF MITOCHONDRIAL FUNCTION</td>
<td><strong>Ana Guerra-Librero</strong>, Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, Granada, Spain</td>
</tr>
<tr>
<td>11:55 – 12:05</td>
<td>HIGH CONCENTRATION OF MELATONIN POTENTIATES THE TOXICITY OF RADIO- AND CHEMOTHERAPY IN HEAD AND NECK CANCER CELLS IN CULTURE AND IN VIVO</td>
<td><strong>Beatriz I Fernandez-Gil</strong>, Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, Granada, Spain</td>
</tr>
<tr>
<td>12:05 – 12:15</td>
<td>MACROPHAGE-BASED TECHNOLOGY FOR CANCER TREATMENT: M3 SWITCH PHENOTYPE EFFECTIVELY RESTRICTS TUMOR GROWTH IN VITRO AND IN VIVO</td>
<td><strong>Dr. Igor Malyshev</strong>, Moscow State University of Medicine and Dentistry, Moscow, Russian Federation</td>
</tr>
<tr>
<td>12:15 – 12:40</td>
<td>Adoptive T cell Therapy for Cancer</td>
<td><strong>Dr Gray Kueberuwa</strong>, Manchester Cancer Research Centre, The University of Manchester, Withington, Manchester, United Kingdom</td>
</tr>
<tr>
<td>12:40 – 13:05</td>
<td>Stem Cell based Therapies for Cancer: Mechanism and Translation into Clinics</td>
<td><strong>Dr. Khalid Shah</strong>, Harvard Medical School, Massachusetts General Hospital, Boston, USA</td>
</tr>
<tr>
<td>13:05 – 14:05</td>
<td>Lunch Break with Exhibitions</td>
<td>Poster viewing</td>
</tr>
<tr>
<td>14:05 – 14:30</td>
<td>Dendritic cell derived exosomes for cancer therapy</td>
<td><strong>Associate Professor Susanne Gabrielsson</strong>, Karolinska Institutet, Dept. of Medicine, Translational Immunology Unit, Stockholm, Sweden</td>
</tr>
<tr>
<td>14:30 – 14:55</td>
<td>Precious metals for cancer treatment - a novel approach</td>
<td><strong>Dr. Isolda Romero-Canelón</strong>, University of Warwick, Coventry, United Kingdom</td>
</tr>
<tr>
<td>14:55 – 15:15</td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td>14:55 – 15:05</td>
<td>EFFICACY OF A NEW PHARMACEUTICAL FORMULATION OF MELATONIN IN PREVENTING RADIONUCLIDE-INDUCED MUCOSITIS</td>
<td><strong>Germaine Escames</strong>, Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, Granada, Spain</td>
</tr>
<tr>
<td>15:05 – 15:15</td>
<td>TARGETING CANCER CELL PROTEIN SYNTHESIS WITH Beta-CARBOLINE DERIVATIVES TO COMBAT BRAIN CANCERS</td>
<td><strong>Anelise Carvalho</strong>, Université Libre de Bruxelles, Brussels, Belgium</td>
</tr>
<tr>
<td>15:15 – 15:45</td>
<td>Last Poster Review and Exhibitions</td>
<td>Refreshments provided</td>
</tr>
<tr>
<td>15:45 – 16:10</td>
<td>Immunotherapy for cancer dormancy</td>
<td><strong>Dr. Masoud H. Manjili</strong>, VCU School of Medicine, Richmond, United States</td>
</tr>
<tr>
<td>16:10 – 16:35</td>
<td>Targeted nanomedicines in cancer therapy</td>
<td><strong>Dr Christine Dufes</strong>, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK</td>
</tr>
<tr>
<td>16:35 – 17:00</td>
<td>Question Time</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Chairman’s Summing Up</td>
<td>Close of Session</td>
</tr>
</tbody>
</table>

PLEASE NOTE: TIMES ARE SUBJECT TO CHANGE
## AGENDA

PLEASE NOTE: DUE TO SECURITY CONTROLS, THERE IS NO ACCESS TO THE VENUE BEFORE 9AM

(Invited Talk times include 5 – 10 minutes for question; Oral presentations include 2-3 minutes for questions)

### Day 2: Genetic Factors and Influences

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:45</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>09:45 – 10:25</td>
<td>Introduction by the Chair</td>
<td>Dr Jing Jie Yu, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, United States</td>
</tr>
<tr>
<td></td>
<td>DNA damage repair and p53 gene in platinum-drug resistance</td>
<td></td>
</tr>
<tr>
<td>10:25 – 10:50</td>
<td>Crosstalk between cell death modalities as anticancer target</td>
<td>Dr Marc Diederich, Department of Pharmacy, College of Pharmacy, Seoul National University, Korea</td>
</tr>
<tr>
<td>10:50 – 11:15</td>
<td>DNA repair gene polymorphisms as risk factors and chemotherapy response predictors for lung adenocarcinoma in Serbia</td>
<td>Ivana Boljevic, Laboratory for Molecular Genetics, Institute for Oncology and Radiology of Serbia, Serbia</td>
</tr>
<tr>
<td>11:15 – 11:45</td>
<td>Poster Review and Exhibitions</td>
<td>Refreshments provided</td>
</tr>
<tr>
<td>11:45 – 12:10</td>
<td>DNA methylation in epithelial-to-mesenchymal transition</td>
<td>Dr. Bozena Smolkova, Cancer Research Institute of Slovak Academy of Sciences, Bratislava, Slovakia</td>
</tr>
<tr>
<td>12:10 – 12:35</td>
<td>p53 regulates miRNA-AGO2 association to control miRNA-mediated post-transcriptional gene repression in cancer</td>
<td>Dr Leandro Castellano, Imperial College London, South Kensington Campus, London, United Kingdom</td>
</tr>
<tr>
<td>12:35 – 13:00</td>
<td>RAD18 is involved in the resistance of glioblastoma cancer stem cells to the therapy</td>
<td>Dr Chames Kermi, Genome Surveillance and Stability Laboratory, Institute of Human Genetics (IGH), Montpellier, France</td>
</tr>
<tr>
<td>13:00 – 13:10</td>
<td>Oral Presentation</td>
<td>Dr Nives Pećina-Šlaus, University of Zagreb, Zagreb, Croatia</td>
</tr>
<tr>
<td></td>
<td>WNT SIGNALLING PATHWAY IS TARGETED IN MENINGIOMA</td>
<td></td>
</tr>
<tr>
<td>13:10 – 14:10</td>
<td>Lunch Break with Exhibitions</td>
<td>Poster viewing</td>
</tr>
<tr>
<td>14:10 – 14:35</td>
<td>Recognition of LINE-1 derived DNA by the cGAS-STING pathway leads to inflammation in Fanconi Anemia</td>
<td>Dr Jessica Guerra, CNRS UPR1142, IGH Molecular Basis of Cancer Related Inflammation, Montpellier, France</td>
</tr>
<tr>
<td>14:35 – 15:00</td>
<td>NQO1, GSTM1, and GSTT1 genetic polymorphisms and the risk of developing cancer among Filipinos</td>
<td>Dr Pia Marie Albano, Research Center for the Natural and Applied Sciences, University of Santo Tomas, Manila, Philippines</td>
</tr>
<tr>
<td>15:00 – 15:25</td>
<td>The stress protein TPS3NIP1 plays a tumor suppressive role by regulating metabolic homeostasis</td>
<td>Dr. Alice Carrier, Cancer Research Center of Marseille (CRCM), Marseille, France</td>
</tr>
<tr>
<td>15:25 – 15:55</td>
<td>Last Poster Review and Exhibitions</td>
<td>Refreshments provided</td>
</tr>
<tr>
<td>15:55 – 16:05</td>
<td>Oral Presentation</td>
<td>Professor Hala Gali-Muhtasib, American University of Beirut, Department of Biology, Beirut, Lebanon</td>
</tr>
<tr>
<td></td>
<td>UPTAKE DYNAMICS OF NANOPARTICLE ENCAPSULATED THYMOQUINONE AND EFFECTIVE TARGETING OF BREAST CANCER CELLS</td>
<td></td>
</tr>
<tr>
<td>16:05 – 16:30</td>
<td>Molecular factors associated with resistance to drugs targeting BRAF in malignant melanoma</td>
<td>Dr Suzanne Egyházi Brage, Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden</td>
</tr>
<tr>
<td>16:30 – 16:55</td>
<td>The antitumor activity of cannabinoids in colorectal cancer</td>
<td>Dr David Meiri, Technion-Israel Institute of Technology, Haifa, Israel</td>
</tr>
<tr>
<td>16:55 – 17:00</td>
<td>Chairman’s Summing Up</td>
<td>Close of Session</td>
</tr>
</tbody>
</table>

PLEASE NOTE: TIMES ARE SUBJECT TO CHANGE
# AGENDA

**PLEASE NOTE: DUE TO SECURITY CONTROLS, THERE IS NO ACCESS TO THE VENUE BEFORE 9AM**

(Invited Talk times include 5 – 10 minutes for question; Oral presentations include 2-3 minutes for questions)

## Day 3: Biomarkers and Diagnostics

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:45</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Introduction by the Chair</td>
<td><strong>Professor Rui Amaral Mendes</strong>, Department of Oral and Maxillofacial Medicine, Case Western Reserve University, Ohio, USA</td>
</tr>
<tr>
<td>10:00 – 10:25</td>
<td>Using chemical and biological data for targeted compound selection and biomarker discovery in cancer and beyond</td>
<td><strong>Dr Andreas Bender</strong>, University of Cambridge, Chemistry Department, Cambridge, UK</td>
</tr>
<tr>
<td>10:25 – 10:50</td>
<td>DNA methylation in early detection and risk prediction of women specific cancers</td>
<td><strong>Prof Martin Widschwendter</strong>, MD, UCL Chair in Women’s Cancer, Department of Gynaecology, University of Pennsylvania, Philadelphia, PA, USA</td>
</tr>
<tr>
<td>10:50 – 11:15</td>
<td>CYP3A variation, hormone levels, breast cancer risk and prognosis</td>
<td><strong>Dr Olivia Fletcher</strong>, Genetic Epidemiology, The Institute of Cancer Research, London, UK</td>
</tr>
<tr>
<td>11:15 – 11:45</td>
<td>Poster Review and Exhibitions</td>
<td>Refreshments provided</td>
</tr>
<tr>
<td>11:45 – 12:10</td>
<td>IV Iron in Anemia of Oncology, Inflammation, and other disorders of Iron deficiency</td>
<td><strong>Dr David Henry</strong>, Vice Chair, Department of Medicine, Clinical Professor of Medicine, University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA, USA</td>
</tr>
<tr>
<td>12:10 – 12:35</td>
<td>Cognitive impairment in patients with glioblastoma: single institution experience</td>
<td><strong>Dr. Ana Misir Krpan</strong>, University Hospital Center Zagreb, Zagreb, Croatia</td>
</tr>
<tr>
<td>12:35 – 13:00</td>
<td>OMICS biomarkers and their implication in cancer control</td>
<td><strong>Dr Mukesh Verma</strong>, National Cancer Institute, National Institutes of Health, Rockville, MD, USA</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Oral Presentation</td>
<td><strong>Dr Bethrand Amaechi Francis NWGU</strong>, Department of Pathology, Faculty of Clinical Medicine, Ebonyi State University/ Federal Teaching Hospital Abakaliki, Nigeria</td>
</tr>
<tr>
<td>13:15 – 14:15</td>
<td>Lunch Break with Exhibitions</td>
<td>Poster viewing</td>
</tr>
<tr>
<td>14:15 – 14:40</td>
<td>Responsive lanthanide complexes for imaging of key cell cycle regulators and inhibition of tumor cells</td>
<td><strong>Dr. Gary Ka-Leung Wong</strong>, Hong Kong Baptist University, Pokfulam, Hong Kong</td>
</tr>
<tr>
<td>14:40 – 14:50</td>
<td>Oral Presentations</td>
<td><strong>Dr Irina Babina</strong>, The Breakthrough Toby Robins Breast Cancer Research Centre, London, United Kingdom</td>
</tr>
<tr>
<td>14:40 – 14:55</td>
<td>MOLECULAR DETERMINANTS OF SENSITIVITY AND RESISTANCE TO FGFR TARGETED THERAPY IN FGFR2-AMPLIFIED GASTRIC CANCERS</td>
<td><strong>Umber Saeed</strong>, Dow University of Health Sciences, Karachi, Pakistan</td>
</tr>
<tr>
<td>14:55 – 15:10</td>
<td>INNOVATIVE APPROACHES IN METABOLOMICS FOR UNDERSTANDING DRUG RESISTANCE IN BREAST CANCER</td>
<td><strong>Prof Martin Widschwendter</strong>, MD, UCL Chair in Women’s Cancer, Department of Gynaecology, University of Pennsylvania, Philadelphia, PA, USA</td>
</tr>
<tr>
<td>15:10 – 15:40</td>
<td>Question Time:</td>
<td>Refreshments provided</td>
</tr>
<tr>
<td>15:40 – 16:10</td>
<td>Last Poster Review and Exhibitions</td>
<td><strong>Dr Mark Eccleston</strong>, Business Development Director, VolitionRx, United Kingdom</td>
</tr>
<tr>
<td>16:10 – 16:35</td>
<td>Nucleosomics®- Revolutionising Cancer Diagnostics</td>
<td><strong>Dr Mark Eccleston</strong>, Business Development Director, VolitionRx, United Kingdom</td>
</tr>
<tr>
<td>16:35 – 17:00</td>
<td>Signalling therapy for cancer: from target proteins to target signalling networks</td>
<td><strong>Dr. Alexey Goltsov</strong>, School of Science, Engineering &amp; Technology, University of Abertay Dundee, Scotland, United Kingdom</td>
</tr>
<tr>
<td>17:00</td>
<td>Chairman’s Summing Up</td>
<td>Close of Session</td>
</tr>
</tbody>
</table>

**PLEASE NOTE: TIMES ARE SUBJECT TO CHANGE**
ABOUT THE SPEAKERS

Anthony J. Berdis, Ph.D., Chair, IACUC Committee, Associate Professor of Chemistry and Biology, Cleveland State University, Cleveland, OH, USA
Dr. Berdis is an Associate Professor in the Department of Chemistry and the Center for Gene Regulation in Health and Disease at Cleveland State University. In addition, he is co-founder and Chief Scientific Officer for Red5 Pharmaceuticals, LLC. He is an internationally recognized expert in the field of the synthesis and biological testing of novel nucleoside analogs as therapeutic and diagnostic agents that target DNA polymerase activity. He has published over 70 research papers and book chapters. His research has been funded by numerous agencies including the National Institutes of Health, the Department of Defense, and the American Cancer Society.

Andreas Bender, University of Cambridge, Chemistry Department, Cambridge, UK
Dr Andreas Bender is a Lecturer for Molecular Informatics with the Centre for Molecular Science Informatics at the Department of Chemistry of the University of Cambridge, leading a group of about 20 staff. In his work, Andreas is involved with the integration and analysis of chemical and biological data, aimed at understanding phenotypic compound action (such as cellular readouts, and also organism-level effects) on a mechanistic level, ranging from compound efficacy to toxicity. He received his PhD from the University of Cambridge as a Cambridge Gates Scholar in 2005 and worked in the Lead Discovery Informatics group at Novartis in Cambridge/MA as well as at Leiden University in the Netherlands before his current post.

Irina Babina, The Breakthrough Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
Irina’s research career commenced by investigating stem-like properties of aggressive types of breast cancer during Ph.D. studies in the Royal College of Surgeons in Dublin. She continued to address clinically relevant questions during her postdoctoral post in Dr. Turner’s lab, ICR, London, where she investigated combinatorial drug approaches in triple negative breast cancer using screening methods. In the past 18 months she proceeded to explore FGFR2 addiction in gastric cancer, to determine effective therapeutic strategies using patient and PDX material. Irina is currently investigating mechanisms of acquired resistance with the aim to establish better therapeutic strategies for treatment of oncogene-addicted cancer.

Ivana Boljevic, Laboratory for Molecular Genetics, Institute for Oncology and Radiology of Serbia, Serbia
Ivana Boljevic, MSc, works as a research assistant in the Laboratory for Molecular Genetics, Department of Experimental Oncology at the Institute for Oncology and Radiology of Serbia. Part of her work is dedicated to molecular diagnostics, while the other part is focused on research, mainly molecular genetics of solid tumors, including lung and ovarian cancer. Currently, she is doing a PhD thesis at The University of Belgrade, Faculty of Biology, focused on finding potential biomarkers of epithelial mesenchymal transition (EMT) in ovarian cancer.

Suzanne Egyházi Brage, Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden
Dr Suzanne Egyhazi Brage obtained her PhD in experimental oncology at Karolinska Institutet, Stockholm, Sweden. She has a long experience in studying underlying resistance mechanisms to chemotherapy, mainly alkylating agents. Her research now focuses on identifying molecular factors associated with resistance to targeted therapies such as BRAF and MEK inhibitors and to find novel therapeutic targets in malignant melanoma.

Annelise Carvalho, Université Libre de Bruxelles, Brussels, Belgium
Mrs Carvalho obtained her Masters degree in Pharmacy in 2012 at the Federal University of Santa Catarina (Brazil). She is now pursuing a PhD at the Université Libre de Bruxelles (Belgium) with a scholarship granted by CAPES/Brazil. Her research interest encompasses the broad field of drug discovery and development. More specifically, her current project aims at deciphering the mechanism of action of a novel beta-carboline derivative as a protein synthesis inhibitor of cancer cells. She received her first Award from the Belgian Association for Neuro-Oncology for her project in December 2015.
Isolda Romero-Canelón, University of Warwick, Coventry, United Kingdom
Isolda joined Warwick from an established academic position in Venezuela. Her research looks into the cellular basis for the mechanism of action of metal-based anticancer agents. This has gained her an international reputation, as shown by the increasing number of invitations to deliver oral contributions in major international conferences. The area of research she has established complements the work carried out in her host group which is directed by Prof. Peter J. Sadler, FRS so it has allowed her to develop an independent network of collaborators within Warwick and beyond. Her research has just secured funding from the Wellcome Trust through the competitive Pathfinder award programme.

Alice Carrier, Cancer Research Center of Marseille (CRCM), Marseille, France
Alice Carrier (PhD) is Principal Investigator at the Cancer Research Center of Marseille (France). She has a long-standing expertise in the link between oxidative stress and cancer. She is interested since many years in the regulation of pro-tumoral inflammation and associated redox dysregulations, which led her to the study of mitochondrial energetic metabolism, the main cell source of energy and free radicals. She is currently leading a research program aiming at deciphering energetic metabolic alterations in cancer, in particular pancreatic cancer. This knowledge could be used to develop preclinical trials with the hope to improve the prognosis of pancreatic cancer.

Leandro Castellano, Imperial College London, South Kensington Campus, London, United Kingdom
Dr Castellano's group interest is the investigation of how non-coding RNAs (ncRNAs) interacting with proteins and DNA control cancer related these phenotypes.

Christine Dufes, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
Dr Christine Dufès is a Senior Lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, in Glasgow. Her research interests include the targeted delivery of drugs and therapeutic genes to tumours and cerebral diseases. She has been awarded the Biochemical Journal Young Investigator Award (2009) and the Tom Gibson Memorial Award (2012) for her research, in addition to the Best Overall Strathclyde Teaching Excellence Award 2013 for her teaching. She sits on the editorial boards for 17 journals.

Marc Diederich, Department of Pharmacy, College of Pharmacy, Seoul National University, Korea
Dr. Marc Diederich focused his research on cancer and leukemia cell signaling pathways and gene expression mechanisms triggered by natural compounds with epigenetic-, anti-inflammatory- and cell death-inducing potential. He was appointed associate Professor of Biochemistry at the College of Pharmacy of Seoul National University in 2012. Marc Diederich’s research focuses on the development of novel anti-cancer drugs with anti-inflammatory and anti-cancer activities as novel chemopreventive and/or chemotherapeutic agents.

Germaine Escames, Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, Granada, Spain
Professor of Physiology. She has been working with melatonin and mitochondria for 20 years. She publishes more than 120 papers, and recently she studies the oncostatic effect of melatonin. She has a patent of a melatonin gel in mucositis and a clinical trial with the gel. She is editiorial board of the Journal of Pineal Rsearch.

Mark Eccleston, Business Development Director, VolitionRx, United Kingdom
Dr. Eccleston is a biotechnology entrepreneur and has held various roles including CEO of Vivamer, a spin out from the University of Cambridge focussed on drug delivery, Director of Programmes at Aim listed ValiRx plc. where he managed preclinical development of an epigenetic therapeutics platform. He is currently Business Development Director at VolitionRx. These activities are carried out through his consultancy company- OncoLytika. Mark obtained a degree in chemistry and PhD Polymer Chemistry for Biomedical Applications from the University of Aston in Birmingham, UK. He later obtained an MBA (Entrepreneurship) from Dundee University through the Royal Society of Edinburghs Enterprise Fellowship Scheme.
Beatriz I Fernandez-Gil, Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, Granada, Spain
Biologist holding a Master's degree in Genetics and Evolution. She is carrying out a PhD in Biomedicine focused on cancer and melatonin research. Her background encompasses a wide range of fields like Microbiology, Forensic Science, Regenerative Medicine, Stem Cells and Cancer.

Olivia Fletcher, Genetic Epidemiology The Institute of Cancer Research, London, United Kingdom
After obtaining a BA in Biochemistry from Oxford University, Olivia moved to the National Institute of Medical Research, London to do her PhD working on regulation of gene expression. During her post-doctoral training she became interested in the genetics of complex traits and took up a position as a lecturer in cancer epidemiology at the London School of Hygiene and Tropical Medicine. In 2005 she moved to the Breakthrough Research Centre to continue her work on the genetic epidemiology of breast cancer and to pursue her interest in the identification and characterization of genetic variants that affect levels of gene expression.

Alexey Goltsov, School of Science, Engineering & Technology, University of Abertay Dundee, Scotland, United Kingdom
Alexey Goltsov, School of Science, Engineering & Technology, Abertay University, Dundee, Scotland, United Kingdom. His research interest is the computational systems biology of cancer therapy. He works on the integration of experimental data on drug effects on signalling and genetic networks into a unified approach to support development of the molecular biomarkers for effective targeted drug therapy. The computational methods and models developed by him are used to elucidate the mechanisms of de novo and acquired drug resistance and inform design and validation of the combination therapy targeting drug escape signalling networks to overcome and prevent drug resistance in cancer cells.

Ana Guerra-Librero, Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, Granada, Spain
Biothecnologist specialized in Immunology. She is working in the Biomedical Research Centre in Granada, doing the PhD studying the effects of melatonin in head and neck cancer. Previously, she did her master thesis in cancer and irradiated mesenchymal stem cells, in the same centre. During her degree, she did a training in the Andalusian Centre of Developmental Biology performing a sub-library of C. elegans.

Gray Kueberuwa, Manchester Cancer Research Centre, The University of Manchester, Withington, Manchester, United Kingdom
Gray Kueberuwa completed a Masters degree in Biochemistry and a DPhil in oncology at the university of Oxford. After completeng a 12 month MRC Centenary research project in at the University of Oxford moved to the University of Manchester to work a Bloodwise research project to improve CAR T cell therapy for CD19+ malignancies.

Hala Gali-Muhtasib, American University of Beirut, Department of Biology, Beirut, Lebanon
Hala Gali-Muhtasib is Professor of Cell Biology at the American University of Beirut (AUB). She received her PhD from Kansas State University in 1990. Her research interests focus on studying the role of natural products in cancer prevention and therapy and identifying the mechanisms of action of anticancer drugs. She is the recipient of several research achievement awards. She is currently the Director of the Center for Drug Discovery at the Faculty of Medicine at AUB, a center that aims to ultimately create developmental paths to new discoveries in the drug discovery field at AUB to help in the advancement of therapies.

Susanne Gabrielsson, Karolinska Institutet, Dept. of Medicine, Translational Immunology Unit, Stockholm, Sweden
Dr. Gabrielsson has after her PhD at Stockholm University and a postdoc at the Curie Institute in Paris, established a group dedicated to exosome research at the Karolinska Institutet, Sweden. She has been a pioneer in the field of immune effects of exosomes. Dr. Gabrielsson was the first to describe the presence of exosomes in bronchoalveolar lavage fluid, and also in breast milk. Her work has revealed that exosomes are major players in lung diseases such as asthma and sarcoidosis. Her work in animal models is giving new insights into how exosome-based cancer vaccines should be designed.
Nikolaos Georgopoulos, Department of Biological Sciences, School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom
Dr Nik T. Georgopoulos’ research mainly focuses on understanding how epithelial carcinogenesis influences proliferation/growth, differentiation and particularly cell responses to death signals triggered by the TNFR family. The aim is to use such knowledge to design tumour-specific cancer therapies. Nik received his BSc (Biochemistry & Genetics) and his Ph.D. (Biochemistry & Molecular Biology) at the University of Leeds. This was followed by a post-doctoral fellowship at the Cancer Research UK Centre at Leeds and an EPSRC-funded research fellowship in the Jack Birch Unit of Molecular Carcinogenesis group at the University of York. He is currently a Senior Lecturer at the University of Huddersfield, where he is the Head of the Cell Death and Cancer group.

Jessica Guerra, CNRS UPR1142, IGH Molecular Basis of Cancer Related Inflammation, Montpellier, France
After performing an internship period at the ICGEB in Triest in the Group of Molecular Virology under the supervision of Alessandro Marcello, working on the regulation of nuclear retention of HIV-1 RNA, she obtained her Master degree from the University of Bologna. She then moved to Geneva at the CMU where she obtained her PhD working on the innate immune response to RNA viruses and the mechanisms of regulation of induced antiviral state. She is currently a post doc in the group of Nadine Laguette at the IGH in Montpellier working on the molecular basis of cancer related inflammation.

David Henry, Vice Chair, Department of Medicine, Clinical Professor of Medicine University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA, USA
David H. Henry, MD is a practicing hematologist/medical oncologist and Clinical Professor of Medicine at the Pennsylvania Hospital in Philadelphia, Pennsylvania where he holds the title of Vice Chairman of the Department of Medicine. He is Editor in Chief of the Journal of Community and Supportive Oncology. For the past 25 years, he has had a special interest in supportive oncology and participated in clinical trials using growth factors to treat cancer related anemia with or without IV iron, neutropenia, thrombocytopenia, and bone metabolism due to bone metastases. Director of the HIV Malignancy Program and Director of the Austrian Medical Student Program at Pennsylvania Hospital

Ana Misir Krpan, University Hospital Center Zagreb, Zagreb, Croatia
Ana Misir Krpan, MD. PhD. was educated at University of Zagreb School of Medicine, Zagreb, Croatia. She had residency in oncology at University Hospital Centre Zagreb. In 2008 she got a Master of Science, entitled ‘Combined Influence of Hyperthermia and Chemotherapies on Melanoma B16-F10 Growth in vivo’ University of Zagreb School of Medicine and in 2012. PhD. doctoral thesis entitled ‘Antitumor activity of newly synthesized 2-phenylbenzothiazole derivatives in vitro and in vivo’. In 2015 she was on educational visit in Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Italy. Since 2012 she is working as a specialist of oncology and radiotherapy, Department of Oncology, Clinical Hospital Centre Zagreb and is a deputy team leader for CNS tumours. She is a lecturer in undergraduate and postgraduate courses at the Department of Medical Oncology University of Zagreb and University of Applied Health Sciences and author and co-author of professional and scientific papers, chapters in text-books and Croatian clinical guidelines for diagnosing, treating and monitoring of adult patients with gliomas of central nervous system.

Chames Kermi, Genome Surveillance and Stability Laboratory, Institute of Human Genetics (IGH), Montpellier, France
After obtaining his Doctorate in Pharmacy (PharmD) from Mentouri University, Dr. Kermi has joined the Research and Development department of Sanofi Pharmaceutics in Montpellier – FRANCE where he obtained his Masters degree in nonclinical R & D of health products from the Pharmacy Faculty of the University of Montpellier working on pharmacokinetics and hepatic uptake. Currently, he is a PhD student in the Institute of Human Genetics (IGH) in Montpellier within the team of Doctor MAIORANO where he is interested in studying functional and molecular interactions between the DNA damage tolerance system and the DNA damage checkpoint.
Recent publication: Kermi et al., Developmental Cell, 2015.

Igor Malyshev, Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
Malyshev Igor is a Head of the Department of Pathophysiology and Head of the Laboratory of Cell Biotechnology, Medical School at the Moscow State University of Medicine and Dentistry; 2. Head of the Laboratory of Stress, Institute of General Pathology and Pathophysiology, Moscow and 3. Adjunct Professor of Biomedical Sciences, University of North Texas Health Science Center, USA. He is a Member of the board of directors of the International Society for Adaptive Medicine and an Editorial board member of Journal of Biosciences and Medicines. He has published 3 books and monographs and 153 full length articles. His scientific interests are immunity, cancer, stress and adaptation.

Masoud H. Manjili, VCU School of Medicine, Richmond, United States
Masoud H. Manjili is an Associate Professor of Immunology at Virginia Commonwealth University (VCU) and Member of Massey Cancer Center. He obtained his PhD in immunology from the University of Sydney, Australia, and completed his postdoctoral fellowship in tumor immunology at Roswell Park Cancer Institute, Buffalo, New York. He has developed an ex vivo protocol for the ex vivo reprogramming of tumor-sensitized immune cells that become refractory to MDSC, and protect the host from cancer development upon adoptive immunotherapy. His research is currently focused on the understanding of cancer dormancy, and developing immunotherapeutic strategies that could control dormant tumor cells and prevent advanced stage cancer.

David Meiri, Technion-Israel Institute of Technology, Haifa, Israel
David Meiri is currently an assistant professor at the Technion-Israel Institute of Technology. He completed his Ph.D. at Tel Aviv University, followed by a postdoctoral fellowship at the Ontario Cancer Institute/University of Toronto. After his postdoctoral research, he took a faculty position at the Technion Israel Institute of Technology, where he presently heads the Laboratory of Cancer Biology and Cannabinoid Research. His research focuses on the therapeutic potential of phytocannabinoids, the unique active compounds of Cannabis. Among other avenues of research, he investigates the anti-metastatic and pro-apoptotic effects of cannabinoids, employing various in vitro and in vivo models.

Bethrand Amaechi Francis NGWU, Department of Pathology, Faculty of Clinical Medicine Ebonyi State University/ Federal Teaching Hospital Abakaliki, Nigeria
Dr B.A.F. Ngwu is a senior lecturer and Consultant Pathologist with Ebonyi State University and Federal teaching Hospital Abakaliki Nigeria. He has B.Sc,(Hons), M.Sc.(Medical Microbiology), Ph.D (Virology); MBBS, MWACP, FMC (path). He is the leader of Cancer Research Team, has been head of department and coordinator for 3rd MBBS professional examination.

Gloria Ogechukwu NGWU, Federal Teaching Hospital Abakaliki Ebonyi State, Department of Obstetrics and Gynaecology, Nigeria
Dr. (Mrs) Gloria O. Ngwu is a resident doctor in the department of Obstetrics and Gynaecology of Federal Teaching Hospital Abakaliki. She is a medical graduate from Ebonyi State University Abakaliki and carried out this study with her consultants in the hospital: DR B.A.F NGWU, and DR (MRS) M.U. AGWU; and Prof G.O. EZEIFEKA and MR E.C.AMADI. She is interested in disease prevention especially, gynaecological oncology. She is married with children.

Nives Pećina-Šlaus, School of Medicine University of Zagreb, Laboratory of Neurooncology, Croatian Institute for Brain Research, Zagreb
Nives Pećina-Slaus is full professor at the department of biology and Head of the Laboratory of neuro-oncology Croatian institute for brain research. She has received her BS in 1990. her MS in 1992. from the University of Zagreb, Faculty of Sciences, and her PhD in the field of molecular oncology in 1998. from Medical School. She was trained at Cold Spring Harbor Laboratory, New York, and at Georgetown University, Washington DC. She was granted 5 scientific projects. Her research has led to more than 100 publications – 54 scientific papers, a book, abstracts and book chapters. Her main fields of research are cancer genetics, Wnt signaling pathway, tumor suppressor genes, oncogenes, genetics of brain tumors. She is a member on editorial boards of Frontiers in Bioscience, Acta Clinica Croatica, Cancer Cell International
and Croatian Medical Journal. She teaches medical biology and was mentor on numberous theses. She was awarded three scientific awards, by Croatian Medical Association, by Academy of Medical Sciences and in 2011. she received National Science Award.

**Bozena Smolkova**, Cancer Research Institute of Slovak Academy of Sciences, Bratislava, Slovakia

Dr. Bozena Smolkova has an expertise in the field of genetic epidemiology and epigenetics. She is focused on the analyses of DNA methylation in various materials (FFPE tumour tissues, serum and peripheral blood) with the aim to detect EMT-associated epigenetic biomarkers for early detection of circulating tumour cells in peripheral blood. She is also interested in dynamics of EMT-related epigenetic alterations and possible adverse epigenetic effects of environmental exposures.

**Khalid Shah**, Harvard Medical School, Massachusetts General Hospital, Boston, USA

Dr Shah is the Director of the Stem Cell Therapeutics and Imaging program at MGH and also a Principal Faculty at Harvard Stem Cell Institute. In recent years, Dr Shah and his team have pioneered major developments in the stem cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology. Dr Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. In an effort of to translate the exciting therapies developed in his laboratory into clinics, he has recently founded biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.

**Umber Saeed**, Dow University of Health Sciences, Karachi, Pakistan

I am twenty three years old Umber Saeed from Karachi, Pakistan. I reflect a diverse personality including ambition, and the qualities of high flexibility and thoughtfulness. I am also a well determined and energetic individual, yet pleasantly calm.

I am a full-time student, motivated by my love for learning and succeeding as I strive to become an outstanding and successful woman in today’s society. I am currently in final year of completing my Pharm-D degree from Dow University of Health Sciences.

Through my passion is working on cancer, I have participated in one national and three international research conferences and secured top positions. I am currently working as an intern in one of the biggest research labs in Pakistan. My aim is to work in the field of research and make useful contribution towards science and technology.

**Mukesh Verma**, National Cancer Institute, National Institutes of Health, Rockville, MD, USA

Dr. Mukesh Verma is a Program Director and Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genetics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Before coming to the DCCPS, he was a Program Director in the Division of Cancer Prevention (DCP), NCI, providing direction in the areas of biomarkers, early detection, risk assessment and prevention of cancer, and cancers associated with infectious agents. Dr. Mukesh Verma holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He did postdoctoral research at Howard University and George Washington University and was a faculty member at Georgetown University. He has published 137 research articles and reviews and edited three books in cancer epigenetics and epidemiology field.

**Gary Ka-Leung Wong**, Hong Kong Baptist University, Pokfulam, Hong Kong

Dr. Ka-Leung Wong (Gary) has his research field which mainly focuses on lanthanide chemistry for spectroscopy studies and molecular imaging. He completed a PhD degree in the University of Hong Kong in 2006, following two-year post-doctoral in the City University of Hong Kong and one-year Royal Society Post-doctoral fellowship with Professor David Parker in Durham. In September 2009, he returned to Hong Kong and joined the department of chemistry in Hong Kong Baptist University as a faculty member. He has published more than 80 papers with h-index 31 (Citations > 2300). He has been bestowed the ERES Junior award in 2015, an international triennial prize by the European Rare Earth Society and has selected international advisory board for Multidisciplinary Chemistry Journal in ChemPlusChem (Wiley Publisher).
Martin Widschwendter, MD, UCL Chair in Women's Cancer, Head of Department, Women's Cancer, Consultant Gynaecological Oncology Surgeon, UCL EGA Institute for Women’s Health, University College London, UK

Martin Widschwendter is Professor in Women’s Cancer, Head of Department of Women’s Cancer, University College London and a Consultant Gynaecological Oncology Surgeon at University College London Hospital. His team focus on early detection, risk prediction and prevention of gynaecological and breast cancer. He leads several international research initiatives in women’s cancer including EpiFemCare (www.epifemcare.eu) and FORECEE (www.forecee.eu). Martin’s particular clinical interest is complex radical laparoscopic and open surgery.

Jing Jie Yu, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, United States

As Director of Molecular Medicine Core Facility at West Virginia University USA, Jing Jie Yu, MD with extensive experience in molecular genetics supports translational and clinical research to other PIs at the WVU Health Sciences Center. Dr. Yu investigations focus on platinum-drug resistance in cancer chemotherapy, especially enhanced repair of platinum-induced DNA-adduct, one of the major mechanisms of acquired platinum resistance. A new platinum drug, dicycloplatin approved by the Chinese FDA in 2012, is under investigation for a potential clinical trial in the USA.
ABOUT THIS EVENT

Discussion Sessions

The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues.

There are three ways you can ask questions:

1. Before the session you can submit your question to Euroscicon staff at the registration desk,
2. Before and during the session you can submit a question or comments, by email, which will be provided on the day of the event
3. During the session you can put your hand up and join in

Session breaks

All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you

Lunch

We have a number of dishes that are gluten free
We have a range of vegetarian dishes which are separated from the meat and fish dishes
We have a number of dishes that are dairy free
Please note that all food has been prepared in an environment where nuts may be present.

Missing Speakers

It is unfortunate that occasionally a speaker cannot attend, most usually due to not getting visas granted, unforeseen personal events or illness. Whilst we do everything possible to ensure that our speakers are present at the event we apologise in advance if you were at a session where a speaker could not attend. We always try to keep our agendas as up to date as possible, however if a speaker cancels the night before an event or on the day, there is little we can do to rectify this.
FREQUENTLY ASKED QUESTIONS ABOUT OUR EVENTS

Is the delegate list available?

Yes this is available to everyone who attends the event and our sponsors.

It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event.

You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.

Can I have the speakers slides?

We cannot give out the slides from our speaker’s presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.

Can I have a notepad?

Notepads and pens are provided in the delegate bags and at the registration desk.

How can I keep up to date with Euroscicon Events?

To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com

I don’t want my photograph on any Euroscicon promotional material

Please let our tech person know.

Is there WIFI?

Yes, please ask registration for log in details.

Can I have a CPD/ CME certificate?

CPD certificates will be available in the exhibition hall after lunch.

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations.

Personal belongings

Please take care of all your personal belonging as Euroscicon cannot be held responsible if an item goes missing from the lecture theatre or the exhibition hall.